Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} has announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100.

A clinical hold is a notification issued by the FDA to a trial sponsor to delay a proposed clinical trial or suspend an ongoing clinical trial. Continue reading